New adolescent polycystic ovary syndrome perspectives

Minerva Pediatrica

Volumn 63, Issue 1, 2011, Pages 35-47

  Alemzadeh, R ^a   Kansra, A R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Polycystic ovary syndrome, etiology; Puberty; Therapeutics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIBIOTIC AGENT; BIGUANIDE DERIVATIVE; FOLLITROPIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SPIRONOLACTONE; STEROID 17ALPHA MONOOXYGENASE;

ACNE; ALOPECIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; ENZYME ACTIVITY; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOLECULAR GENETICS; OBESITY; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

ACNE VULGARIS; ADOLESCENT; ALGORITHMS; ANDROGEN ANTAGONISTS; ANOVULATION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CONTRACEPTIVE AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EXERCISE THERAPY; FEMALE; HIRSUTISM; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; OBESITY; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TREATMENT OUTCOME;

EID: 79956326262     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11. (Pubitemid 30644187)
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9. (Pubitemid 38766360)
3. Hashemipour M, Faghihimani S, Zolfaghary B, Hovsepian S, Ahmadi F, Haghighi S. Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran. Horm Res 2004;62:278-82.
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
5. Diamanti-Kandarakis E, Panidis D. Unravelling the pheotypic map of polycystic ovaries syndrome (PCOS):a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007;67:735-42.
6. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome:clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717-23. (Pubitemid 40824804)
7. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have different metabolic profile associated with increasing androgen. Fertil Steril 2009;92:626-34.
8. Legro RS. Polycystic ovary syndrome and cardiovascular diseases premature association? Endocrine Rev 2003;24:302-12.
9. Ehrmann DA. Polycystic ovary syndrome. New Eng J Med 2005;352:1223-36.
10. Hardiman O, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2. (Pubitemid 36638434)
11. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492-7. (Pubitemid 43236914)
12. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 2010;162:1093-9.
13. Diamanti-Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol 2010;24:173-83.
14. McCartney CR, Prendergast KA, Chhabra S, Eagleson CA, Yoo R, Chang JF et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls:obesity as a potential factor in the genesis of postpubertal hyperandrogenesim. J Clin Endocrinol Metab 2006;91:1714-22.
15. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787-96. (Pubitemid 46465641)
16. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006;60:759-63. (Pubitemid 44789522)
17. Caprio S, Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS et al. Increased insulin secretion in puberty:a compensatory response to reductions in insulin sensitivity. J Pediatr 1989;114:963-7.
18. Battaglia C, Regnani G, Mancini F, Iughetti L, Flamigni C, Vanturoli S. Polycystic ovaries in childhood:a common finding in daughters of PCOS patients. A pilot study. Hum Reprod 2002;17:771-6. (Pubitemid 34232450)
19. Jahanfar S, Eden JA, Warren P, Seppala M, Nguyen TV. A twin study of polycystic ovary syndrome. Fertil Seril 1995;63:478-86.
20. Legro RS, Drsicoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956-60. (Pubitemid 29003738)
21. Recabarren SE, Smith R, Rios R, Maliqueo M, Echiburu B, Codner et al. Metabolic profile in sons of women with polycyctic syndrome. J Clin Endocrinol Metab 2008;93:1820-6. (Pubitemid 351656524)
22. Coviello AD, Sam S, Legro RS, Dunaif A. High prevalence of metabolic syndrome in first-degree male relatives of women with PCOS is believed to be related to high rates of obesity. J Clin Endocrinol Metab 2009;94:4361-6.
23. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Pérez-Bravo F. Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002;45:959-64. (Pubitemid 34762190)
24. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2031-6. (Pubitemid 36549872)
25. Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS. Hyperandrogenism and hyper-insulinism in children of women with polycystic syndrome:A controlled study. J Clin Endocrinol Metab 2008;93:1662-9. (Pubitemid 351656502)
26. Azziz R. Polycystic syndrome is a family affair. J Clin Endocrinol Metab 2008;93:1579-81.
27. Sir-Petermann T, Hitchsfeld C, Maliqueo M, Codner E, Echiburu B, Gazitua R et al. Birthweight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005;20:2122-6. (Pubitemid 41418494)
28. Laitinen J, Taponen S, Martikainen H, Pouta A, Milwood I, Hartikainen AL et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710-5. (Pubitemid 36712955)
29. Givens JR. Familial polycystic ovarian disease. Endocrinol Metab Clin N Am USA 1988;17:771-83. (Pubitemid 19005977)
30. Urbanek M, Spielman RS. Genetic analysis of candidate genes for the polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 2002;9:492-501. (Pubitemid 36735168)
31. Abott DH, Dumesic DA, Franks S. Developmental origin of polycystic syndrome-a hypothesis. J Endocrinol 2002;174:1-5. (Pubitemid 34830927)
32. Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002;78:1240-3. (Pubitemid 35469148)
33. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol 2002;147:717-25. (Pubitemid 36032959)
34. Legro RS, Strauss JF. Molecular progress. in infertility:polycystic ovary syndrome. Fertil Seril 2002;78:569-76.
35. Wood JR, Nelson VL, HO C, Jansen E, Wang CY, Urbanek M et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate genes defined by microarray analysis. J Biol Chem 2003;278:26380-90. (Pubitemid 36876777)
36. Christopoulos P, Mastorakos G, Gazouli M, Panidis D, Deligeoroglou E, Katsikis I et al. Genetic variants in TCF7L2 and KCNJ11 genes in a Greek population with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:486-90.
37. San-Millán JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS):an original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf) 2010;72:383-92.
38. Tan S, Scherag A, Janssen OE, Hahn S, Lahner H, Dietz T et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 2010;11:12.
39. Yoshihara K, Yahata T, Kashima K, Mikami T, Tanaka K. Association of single nucleotide polymorphisms in adiponectin and its receptor genes with polycystic ovary syndrome. J Reprod Med 2009;54:669-74.
40. Urbanek M, Woodroffe A, Ewens KG, Diamanti-Kandarakis E, Legro RS, Strauss JF III et al. Candidate gene for polycystic ovary syndrome on chromosome 19p132. J Clin Endocrinol Metab 2005;90:6623-9. (Pubitemid 41759325)
41. Ewens KG, Stewart DR, Ankener W, Urbanek M, McAllister JM, Chen C et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab 2010;95:2306-15.
42. Premoli AC, Santana LF, Ferriani RA, Moura MD, De Sa MF, Reis RM. Growth hormone secretion and insulin-like growth factor-1 are related to hyperandrogenism in nonobese patients with polycystic ovary syndrome. Fertil Steril 2005;83:1852-5. (Pubitemid 40824828)
43. Falcone T, Finegood DT, Fantus IG, Morris D. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab 1990;71:1653-7. (Pubitemid 120032789)
44. Diamond MP, Grainger DA, Laudaro AJ. Effect of acute physiological elevations of insulin on circulating androgen levels in normal women. J Clin Endocrinol Metab 1991;72:883-7. (Pubitemid 21921781)
45. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in normal and polycystic ovary. Endocrinol Metab North Am 1999;28:361-8.
46. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 2004;18:685-706. (Pubitemid 40424605)
47. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC. Polycystic ovary syndrome:evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by Estradiol and progesterone. J Clin Endocrinol Metab 1998;83:582-90.
48. Blank SK, McCartney CR, Chhabra S, Helm KD, Eagleson CA, Chang RJ et al.Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls-implications for regulation of pubertal maturation. McCartney CR, Blank SK, Marshall JC. J Clin Endocrinol Metab 2009;94:2360-6.
49. Eaglson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS et al. Polycystic ovarian syndrome:evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-52. (Pubitemid 32055351)
50. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007;8:201-19. (Pubitemid 47195665)
51. Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 1995;98:80S-88S.
52. Kealey T, Philpott M, Guy R. Human pilosebaceous culture. Methods Mol Biol 1997;75:101-15.
53. Shah NA Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:1939-45. (Pubitemid 351656541)
54. Tsutsumi O. Assessment of human contamination of estrogenic endocrine-disrupting chemicals and their risk for human reproduction. J Steroid Biochem Mol Biol. 2005;93:325-30. (Pubitemid 40602507)
55. Fernandez MO, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Health Perspect 2010;118:1217-22.
56. Kandaraki E, Chatzigeorgiou A, Palioura E, Economou F, Livadas S, Koutsilieris M et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated blood levels of bisphenol a in PCOS women. Endocrine Society Meeting 2010;Absrtact# P2-395.
57. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome:towards a rational approach. In: Dunaif AGJ, Haseltine F, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377-84.
58. Azziz R, Legro RS, Norman RJ, Taylor AE. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-45. (Pubitemid 44833391)
59. Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril 2006;86 Suppl 1:S6 (Pubitemid 43949267)
60. Apter D, Butzow T, Laughin GA, Yen SS Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. JCEM 1994;79:119.
61. Rieder J, Santoro N, Cohen HW. Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. J Adol Health 2008;43:115-24.
62. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005;34:677-705.
63. Venturoli S, Porcu E, Fabbri R. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab 1992;74:836-41.
64. Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem 2006;43(Pt 3):217-9.
65. Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril 2000;74:49-58. (Pubitemid 30427272)
66. Shayya R, Chang RJ. Reproductive endocrinology of adolescent polycystic ovary syndrome. BJOG 2010;117;150-5.
67. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941-5. (Pubitemid 43357762)
68. Park A, Wachs D, Coffler M, Yoo R, Chang R. Serum anti-mullerian hormone concentrations in oligomenorrheic adolescents without evidence of hyperandrogenism and girls with polycystic syndrome. Ann Mtg Soc Gyn Invest 2007;14:202A-203A.
69. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
70. Blume-Peytavi U, Hillmann K, Guarrera M. Hair growth assessment techniques. In: Blume-Peytavi U, Tosti A, Whiting DA, editors. Hair growth and disorders. Berlin-Heidelberg, Germany: Springer-Verlag; 2008. p. 125-57.
71. Li L, Yang D, Chen X, Chen Y, Feng S, Wang L. Clinical and metabolic features of polycystic ovary syndrome. Int J Gynaecol Obstet 2007;97:129-34. (Pubitemid 46589453)
72. Ozdemir S, Ozdemir M, Görkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand 2010;89:199-204.
73. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Ekkel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
74. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15:477-88.
75. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. 2004 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-35.
76. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. 2004 Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women:the atherosclerosis risk in communities study. Am J Epidemiol 160:540-8. (Pubitemid 39215630)
77. Azziz R. Diagnosing the diagnosis:why we must standardize the defining features of polycystic ovary syndrome. Ann Clin Biochem 2008;45(Pt 1):3-5. (Pubitemid 351724607)
78. Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts 2009;2:26-35.
79. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:162-8.
80. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes (Lond). 2007;31 Suppl 2:S8-S13. (Pubitemid 350023168)
81. Norman RJ, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine 2006;30:35-43. (Pubitemid 46020328)
82. Otta CF, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, Wyse EP. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome:a randomized, double-blind, and placebo control trial. Gynecol Endocrinol 2010;26:173-8.
83. Porcile A, Gallardo E. long-term treatment of hirsutism:desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril 1991;55:877-81.
84. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues:new perspectives and unifying hypothesis. Hum Reprod 2007;22:317-22. (Pubitemid 46156598)
85. Mowszowicz I, Wright F, Vincens M, Rigaud C, Nahoul K, Mavier P et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 1984;20:757-61. (Pubitemid 14125080)
86. Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005;28:49-53. (Pubitemid 43162809)
87. Sahin I, Serter R, Karakurt F, Demirbas B, Culha C, Taskapan C et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome:a randomized prospective study. Gynecol Endocrinol 2004;19:115-24. (Pubitemid 39486897)
88. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102. (Pubitemid 28498317)
89. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome:a comprehensive review. Endocr Rev 2009;30:1-50.
90. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Eng J Med 2008;358:47-54.
91. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson M. Insulin sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease and endometrial carcinoma in polycystic ovary syndrome. Cochrane Database of Syst Rev 2007;CD0005552.
92. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-9. (Pubitemid 34615238)
93. Glueck CJ, Aregawi D, Winiarska M, Agloria M, Luo G, Sieve L et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2006;19:831-42.
94. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinemic obese patients with polycystic ovary syndrome. Hum Reprod. 2003;18:1210-8. (Pubitemid 36740566)
95. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93:4299-306. (Pubitemid 352789525)